Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zipalertinib food-effect pharmacokinetic study in EGFR-mutant NSCLC
jRCT2031260096Phase 1Recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zipalertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Maximum observed plasma concentration, Area under the concentration-time curve from time zero to last measurable concentration and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
zipalertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031260096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260096.